Open Access Could Transform Drug Discovery: A Case Study of JQ1
Open Access
- 6 February 2016
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Drug Discovery
- Vol. 11 (3), 321-332
- https://doi.org/10.1517/17460441.2016.1144587
Abstract
Introduction: The cost to develop a new drug from target discovery to market is a staggering $1.8 billion, largely due to the very high attrition rate of drug candidates and the lengthy transition ...Keywords
Funding Information
- Saïd Foundation
- SENS Research Foundation
- CASMI Translational Stem Cell Consortium
- Oxford NIHR MSK BRU
This publication has 48 references indexed in Scilit:
- Breaking Down Translation Barriers: Investigator’s PerspectiveScience Translational Medicine, 2014
- Commercializing biomedical research through securitization techniquesNature Biotechnology, 2012
- Diagnosing the decline in pharmaceutical R&D efficiencyNature Reviews Drug Discovery, 2012
- The impact of mergers on pharmaceutical R&DNature Reviews Drug Discovery, 2011
- The problems with today's pharmaceutical business—an outsider's viewNature Biotechnology, 2011
- How to improve R&D productivity: the pharmaceutical industry's grand challengeNature Reviews Drug Discovery, 2010
- Is open innovation the way forward for big pharma?Nature Reviews Drug Discovery, 2010
- Lessons from 60 years of pharmaceutical innovationNature Reviews Drug Discovery, 2009
- Cutting the cost of drug development?Nature Reviews Drug Discovery, 2004
- The Changing Structure Of The Pharmaceutical IndustryHealth Affairs, 2004